Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16079863 | 0.89 | NLRP3 (0.51) | RECQLMAPTNLRP3PTGDR2 | |
| SCHEMBL13840487 | 0.86 | NLRP3 (0.41) | RECQLMAPTNLRP3PTGDR2 | |
| SCHEMBL14880280 | 0.85 | CA1 (0.52) | RECQLKDM4ENPC1RAB9AMAPT | |
| SCHEMBL2921233 | 0.84 | POLB (0.44) | KDM4EMAPT | |
| SCHEMBL2920830 | 0.83 | KDM4E (0.47) | RECQLKDM4EMAPTNLRP3PTGDR2 | |
| SCHEMBL2912606 | 0.81 | PYGL (0.46) | KDM4EMAPTNLRP3PTGDR2 | |
| SCHEMBL14880281 | 0.81 | CRBN (0.44) | KDM4EPTGDR2 | |
| SCHEMBL2923835 | 0.81 | RECQL (0.45) | RECQLPKMKDM4ENPC1RAB9A | |
| SCHEMBL3983896 | 0.80 | RECQL (0.46) | RECQLPKMKDM4ENPC1RAB9A | |
| SCHEMBL16079862 | 0.80 | ORAI1 (0.42) | PKMNPC1RAB9AMAPTNLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278942-B2 | Non-steroidal compounds as androgen receptor modulators | FLX DISCOVERIES OY (FI) | 2016-03-08 | — | — | US | disclosed |
| US-9278942-B2 | Non-steroidal compounds as androgen receptor modulators | FLX DISCOVERIES OY (FI) | 2016-03-08 | — | — | US | disclosed |
| US-9278942-B2 | Non-steroidal compounds as androgen receptor modulators | FLX DISCOVERIES OY (FI) | 2016-03-08 | — | — | US | disclosed |
| US-20140275186-A1 | NOVEL NON-STEROIDAL COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | FLX DISCOVERIES OY (FI) | 2014-09-18 | — | — | US | disclosed |
| US-20140275186-A1 | NOVEL NON-STEROIDAL COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | FLX DISCOVERIES OY (FI) | 2014-09-18 | — | — | US | disclosed |
| US-20140275186-A1 | NOVEL NON-STEROIDAL COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | FLX DISCOVERIES OY (FI) | 2014-09-18 | — | — | US | disclosed |
| EP-2768814-A1 | NOVEL NON-STEROIDAL COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | FLX Discoveries OY (FI) | 2014-08-27 | — | — | EP | disclosed |
| WO-2013057372-A1 | NOVEL NON-STEROIDAL COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | PULKKINEN JUHA (FI) | 2013-04-25 | — | — | WO | disclosed |
| WO-2013057372-A1 | NOVEL NON-STEROIDAL COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | PULKKINEN JUHA (FI) | 2013-04-25 | — | — | WO | disclosed |
| US-20100267784-A1 | NOVEL 4,5-DIHYDROISOXAZOLES WITH ESTROGENIC ACTIVITY | PULKKINEN JUHA | 2010-10-21 | — | — | US | disclosed |
| US-20100267784-A1 | NOVEL 4,5-DIHYDROISOXAZOLES WITH ESTROGENIC ACTIVITY | PULKKINEN JUHA | 2010-10-21 | — | — | US | disclosed |
| US-20100267784-A1 | NOVEL 4,5-DIHYDROISOXAZOLES WITH ESTROGENIC ACTIVITY | PULKKINEN JUHA | 2010-10-21 | — | — | US | disclosed |
| EP-2222653-A1 | NOVEL 4,5-DIHYDROISOXAZOLES WITH ESTROGENIC ACTIVITY | Pulkkinen, Juha (FI) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009066009-A1 | NOVEL 4,5-DIHYDROISOXAZOLES WITH ESTROGENIC ACTIVITY | PULKKINEN JUHA (FI) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009066009-A1 | NOVEL 4,5-DIHYDROISOXAZOLES WITH ESTROGENIC ACTIVITY | PULKKINEN JUHA (FI) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267784-A1 | NOVEL 4,5-DIHYDROISOXAZOLES WITH ESTROGENIC ACTIVITY | ESR2, GPER1, CYP19A1 | RECQL 3988/4885PKM 2832/4885KDM4E 774/4885 |
| US-20140275186-A1 | NOVEL NON-STEROIDAL COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, NR5A1, SHBG | RECQL 4403/4885PKM 2792/4885KDM4E 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.